News Related to Bexobrutideg

Related coverage linked through entity extraction aliases.

Nurix Highlights Oncology and Immunology Degrader Pipeline Progress

May 18, 2026

Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.

Drug Hunter's Most Popular Content of 2025 Highlights Industry Trends

Dec 30, 2025

Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.